Antihypertensives Triggering Bullous Pemphigoid
Loop diuretics (particularly furosemide) and aldosterone antagonists are the antihypertensive drug classes with the strongest evidence for triggering bullous pemphigoid, followed by ACE inhibitors (captopril, enalapril) and angiotensin receptor blockers (valsartan).
Primary Offending Antihypertensive Classes
Diuretics - Strongest Evidence
- Loop diuretics show the most robust association, with furosemide demonstrating strong statistical correlation (PRR = 7.2, IC025 = 2.6) and 301 reported cases in the FDA adverse event database 1
- Aldosterone antagonists (spironolactone) carry a 3-fold increased risk (adjusted OR 3.1,95% CI 1.4-7.1) based on case-control data 2
- General diuretic use shows 1.8-fold increased odds of bullous pemphigoid (adjusted OR 1.8,95% CI 1.1-2.9) 2
ACE Inhibitors
- Captopril has documented case reports of inducing bullous pemphigoid, with lesions appearing approximately 50 days after initiation 3
- Enalapril has been reported to trigger mucous membrane pemphigoid, with lesions resolving after drug discontinuation 4
Angiotensin Receptor Blockers
- Valsartan has been implicated in mucocutaneous bullous pemphigoid 5
Clinical Recognition Algorithm
When evaluating a patient with new-onset bullous pemphigoid:
Review medication history for the past 2-6 months, focusing on:
- Any diuretics (especially furosemide, spironolactone)
- ACE inhibitors or ARBs
- Recent antihypertensive changes or dose escalations
Temporal relationship: Drug-associated bullous pemphigoid typically develops 50-180 days after drug initiation 3
Clinical presentation: Identical to idiopathic bullous pemphigoid (pruritus → urticarial plaques → tense bullae) 6
Management Approach
Immediately discontinue the suspected antihypertensive agent and substitute with an alternative class not associated with bullous pemphigoid (e.g., calcium channel blockers, beta-blockers). This is critical because:
- Drug withdrawal alone may lead to resolution in some cases 4
- Continued exposure perpetuates the autoimmune response
- Earlier cessation improves outcomes and may reduce need for immunosuppression 7
After drug discontinuation, initiate standard bullous pemphigoid treatment per established guidelines 8:
- Topical clobetasol propionate 0.05% (10-40g daily depending on extent)
- Systemic corticosteroids (prednisone 0.5-0.75 mg/kg/day) for extensive disease
Critical Caveats
Do not assume all antihypertensives are safe alternatives. The systematic review identified 89 drugs total associated with drug-induced bullous pemphigoid 6, though the evidence is strongest for the classes listed above.
Elderly patients on polypharmacy require heightened vigilance since bullous pemphigoid predominantly affects this population and they often take multiple potential triggers simultaneously 2.
The association is not dose-dependent - even standard therapeutic doses can trigger the condition 3.
Evidence Quality Note
While the 2015 European guidelines 8 provide excellent treatment algorithms, they do not address drug-induced triggers. The strongest evidence for specific antihypertensive associations comes from the 2025 FDA adverse event database analysis 1 showing disproportionality signals, supported by the 1996 case-control study 2 demonstrating statistical associations with diuretics and aldosterone antagonists specifically.